Answers are grounded in this paper and cite their sources.
To the Editor: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive brain tumor that primarily affects infants. Its genetic hallmark is biallelic inactivation of members of the SWI/SNF chromatin remodeling complex, most commonly SMARCB1 and, rarely, SMARCA4. Most AT/RTs arise de novo; however, unusual secondary AT/RTs evolving from other less aggressive precursor tumors, such as pleomorphic xanthoastrocytoma (PXA),1–5 or ganglioglioma,6,7 have been reported, with the former being the most common precursor lesion. In most secondary AT/RTs, pathological analysis reveals a dimorphic tumor containing a component of the precursor tumor with retained nuclear expression of SMARCB1 as well as an AT/RT component with SMARCB1 loss.1,3,4,6,7 Both components shared the same genetic alterations, such as BRAF V600E mutation, supporting their common origin.3,4,7 On the other hand, biallelic inactivation of SMARCB1 (22q11.2) was identified only in the AT/RT component, suggesting that it arose through acquisition of the SMARCB1 alteration in a pre-existing tumor.1,7 Compared with conventional AT/RTs, secondary AT/RTs tend to occur in older patients and be composed largely of rhabdoid cells.8,9
No takes yet. Share an insight, caveat, or question.
Okuno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: